Finally, clinical trials evaluating the efficacy of monoclonal antibodies against IP-10, IFN-γ, and other IFN proteins in LN patients may lead to new therapeutic options and personalized treatments for patients with high serum and urine levels of IP-10, in high-risk populations (i.e., African American), or those non-responsive to standard therapeutics. The gene discussed is CXCL10; the disease is lobular neoplasia.